XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer

Exclusion Criteria

• •1. Previous treatment with mitoxantrone
• •2. Previous treatment with \<225 mg/m\^2 cumulative dose of Taxotere (or docetaxel)
• •3. Prior radiotherapy to ≥ 40% of bone marrow
• •4. Surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrollment in the study
• •5. Other prior malignancy, except for adequately treated superficial basal cell skin cancer, or any other cancer from which the patient has been disease-free for less than 5 years
• •6. Known brain or leptomeningeal involvement
• •7. Other concurrent serious illness or medical conditions
• •8. Inadequate organ function evidenced by unacceptable laboratory results
• •The investigator will evaluate whether there are other reasons why a patient may not participate.